Journal articleExpert Rev Pharmacoecon Outcomes Res2021
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
- Journal
- Expert Rev Pharmacoecon Outcomes Res
- Published
- 25 September 2020
- Citations
- 12
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try